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Soluble guanylyl cyclase (sGC), the best-established nitric
oxide receptor is a heterodimeric heme-protein synthesiz-
ing cGMP upon NO binding to its Fe(II)heme. cGMP in
turn plays an important role in the regulation of vascular
tone and platelet aggregation. The redox state of the sGC
heme is fundamental for the activation by NO. A novel
class of sGC activators, such as the recently described BAY
58-2667, are however NO-independent and target sGC in
its Fe(III) and heme-free state. Given the therapeutic
potential of such sGC activators, the mechanisms that
modulate the sensitivity of sGC towards these agonists is
of great interest. In this study we found, that treatment of
primary porcine pulmonary artery endothelial cells with
the NO donor DETA-NO (100 µmol/l) leads to a down-
regulation of DEA-NO stimulated and an up-regulation of
BAY 58-2667 stimulated sGC activities (pmol/106 cells)
[DEA-NO: 4.83 ± 0.11 vs. 3.02 ± 0.08***, BAY 58-2667:
0.77 ± 0.01 vs. 1.91 ± 0.04***; control vs. 2 h DETA-NO
pre-treatment]. Furthermore, we observed a down-regula-
tion of sGC (α1/β1) protein levels upon treatment with
DETA-NO in a dose- and time-dependent manner. Inter-
estingly, the decrease in protein levels (maximal at t = 72
h: 56.7 ± 7% of control for sGC α1 and 44.4 ± 8% of con-
trol for sGC β1) occured subsequent to the apparent
reduction in NO stimulatable sGC activity (maximal at t =
2 h). Downregulation of cellular cGMP responses has
recently been attributed to upregulation of cGMP break-
down via enhanced PDE5 activity. Thus we tested the
effects of the cGMP analogue 8-Br-cGMP (125/250/500
µmol/l), the mixed NO-independent sGC activator and
PDE inhibitor YC-1 (10/50/100 µmol/l) and the selective
phosphodiesterase-5 inhibitor zaprinast (50/100/200
µmol/l) on sGC protein levels. In contrast to DETA-NO,
none of these modulators altered sGC protein expression
arguing against a cGMP/PDE dependent mechanism. To
determine if endogenously produced NO mimicked the
effects of DETA-NO on sGC we utilised two models. First,
porcine endothelial cells were pretreated with the
endothelial NO synthase (eNOS) inhibitor L-NAME (100
µmol/l from 2 to 72 hours) and, second, aortas from
eNOS deficient mice were investigated. L-NAME induced
changes in endothelial NO and BAY 58-2667 stimulated
sGC activity, that were reciprocal to those observed with
DETA-NO treatment. While sGC expression and the
response to DEA-NO were enhanced, the response to BAY
58-2667 was un-altered. Concurrent to these findings, in
aortic homogenates from eNOS -/- mice, an increased
DEA-NO induced sGC response was observed as com-
pared to wild type controls. In conclusion, our data sug-
gests endogenous regulation of the sGC redox state via
NO. The decrease in the cGMP response to DEA-NO and
the increase to BAY 58-2667 induced cGMP production
following DETA-NO pretreatment, indicates a change in
the redox state of the sGC heme from a ferrous to ferric or
even heme free. Furthermore, these changes in the redox
state of sGC, seem to induce a protein degradation of sGC
(α1/β1). Hence, desensitization of the NO/cGMP-path-
way is heterogenous, occurring either as a result of PDE-5
upregulation or, as in pulmonary endothelial cells, via a
PDE-5-independent mechanism involving a change in
sGC redox state and protein stability.
from 2nd International Conference of cGMP Generators, Effectors and Therapeutic Implications
Potsdam, Germany, 10–12 June, 2005
Published: 16 June 2005
BMC Pharmacology 2005, 5(Suppl 1):P13 doi:10.1186/1471-2210-5-S1-P13
<supplement> <title> <p>2nd International Conference of cGMP Generators, Effectors and Therapeutic Implications</p> </title> <note>Meeting abstracts</note> </supplement>
